Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer

被引:33
作者
Kim, Seok-Hyun [1 ]
Lee, Hyoun Wook [2 ]
Go, Se-Il [3 ,4 ]
Lee, Soon Il [5 ]
Lee, Gyeong-Won [4 ,6 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Div Hematol & Med Oncol,Dept Internal Med, Chang Won, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Pathol, Chang Won, South Korea
[3] Gyeongsang Natl Univ, Changwon Hosp, Dept Internal Med, Div Hematol Oncol, Chang Won, South Korea
[4] Gyeongsang Natl Univ, Gyeongsang Natl Univ Hosp, Dept Internal Med, Div Hematol Oncol,Sch Med, Jinju, South Korea
[5] Dankook Univ, Coll Med, Dept Internal Med, Cheonan, South Korea
[6] Gyeongsang Natl Univ, Sch Med, Gyeongsang Inst Hlth Sci, Jinju, South Korea
关键词
non-small cell lung cancer; platelet-to-lymphocyte ratio; thrombocytosis; inflammation; prognosis; PHASE-III; CHEMOTHERAPY; PROGNOSIS; SURVIVAL; IMMUNE;
D O I
10.18632/oncotarget.8809
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to assess the prognostic significance of the preoperative platelet count (PLT) and platelet-to-lymphocyte ratio (PLR) in patients with surgically resected non-small-cell lung cancer (NSCLC). Patients and Methods: We retrospectively reviewed 202 patients treated for NSCLC between January 2002 and December 2007. Preoperative PLT and PLR scores were calculated using data obtained at the time of admission. Patients were assigned a PLT-PLR score of 0, 1, or 2 based upon the presence of thrombocytosis, an elevated PLR, or both. Results: Patients with a PLT-PLR score of 2 had a significantly lower median overall survival (OS) [12.715 mo; 95% confidence interval (CI) 1.215-24.215] when compared with patients with PLT-PLR scores of 1 (52.238 mo; 95% CI 17.062-87.414, p = 0.002) or 0 (not reached, p < 0.001). Relapse-free survival (RFS) was also significantly decreased in patients with a PLT-PLR score of 2 (10.107 mo; 95% CI 3.388-16.826) relative to patients with a PLT-PLR score of 1 (27.214 mo; 95% CI 0-56.253, p = 0.002) or 0 (58.893 mo; 95% CI 32.938-84.848, p < 0.001). In multivariate analysis, a PLT-PLR score of 2 was an independent prognostic factor for poor OS (hazard ratio (HR) 3.473; 95% CI 1.765-6.835, p < 0.001) and RFS (HR 2.286; 95% CI 1.243-4.206, p = 0.008) compared with a PLT-PLR score of 0. Conclusions: Preoperative PLT-PLR scores can be useful for predicting disease prognosis in patients with surgically resected NSCLC. Further large prospective studies will be necessary to validate our findings.
引用
收藏
页码:36198 / 36206
页数:9
相关论文
共 31 条
[1]   DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS [J].
ALTMAN, DG ;
LAUSEN, B ;
SAUERBREI, W ;
SCHUMACHER, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :829-835
[2]  
[Anonymous], PROGNOSTIC ROLE PRET
[3]   Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer [J].
Balermpas, Panagiotis ;
Roedel, Franz ;
Weiss, Christian ;
Roedel, Claus ;
Fokas, Emmanouil .
ONCOIMMUNOLOGY, 2014, 3 (01)
[4]   The platelet contribution to cancer progression [J].
Bambace, N. M. ;
Holmes, C. E. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (02) :237-249
[5]   Pathologic Upstaging in Patients Undergoing Resection for Stage I Non-Small Cell Lung Cancer: Are There Modifiable Predictors? [J].
Bott, Matthew J. ;
Patel, Aalok P. ;
Crabtree, Traves D. ;
Colditz, Graham A. ;
Kreisel, Daniel ;
Krupnick, A. Sasha ;
Patterson, G. Alexander ;
Broderick, Stephen ;
Meyers, Bryan F. ;
Puri, Varun .
ANNALS OF THORACIC SURGERY, 2015, 100 (06) :2048-2054
[6]   Immune Regulation of Cancer [J].
Disis, Mary L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) :4531-4538
[7]  
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[8]   The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Goldstraw, Peter ;
Crowley, John ;
Chansky, Kari ;
Giroux, Dorothy J. ;
Groome, Patti A. ;
Rami-Porta, Ramon ;
Postmus, Pieter E. ;
Rusch, Valerie ;
Sobin, Leslie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714
[9]   Platelet-Cancer Interactions [J].
Goubran, Hadi A. ;
Stakiw, Julie ;
Radosevic, Mirjana ;
Burnouf, Thierry .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (03) :296-305
[10]   A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens [J].
Hainsworth, John D. ;
Cebotaru, Cristina L. ;
Kanarev, Vladimir ;
Ciuleanu, Tudor E. ;
Damyanov, Danail ;
Stella, Phillip ;
Ganchev, Hristo ;
Pover, Gillian ;
Morris, Clive ;
Tzekova, Valentina .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) :1630-1636